Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant
Last magenta therapeutics, inc earnings: 11/13 08:00 am
Check Earnings Report
-- A single dose of MGTA-145 plus plerixafor mobilized two to three times more stem cells in non-human primates than multi-day regimen of current standard of care G-CSF -- -- Cells mobilized with MGTA-145 plus plerixafor rapidly engrafted in non-human primates following autologous transplant -- -- MGTA-145-mobilized cells from non-human primates suppressed GvHD and extended survival in preclinical models -- -- MGTA-145 to enter the clinic in the first half of 2019 -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented new preclinical research on its MGTA-145 product candidate for stem cell mobilization at the Transplant and Cellular Therapy (TCT) annual meeting. Magenta is deve
[Read more]
| Impact snapshot | Event time: | MGTA | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
MGTA alerts
MGTA alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTA alerts
High impacting Magenta Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
MGTA
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTAGlobeNewswire
- Magenta Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ: MGTA</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.50 priceMarketBeat
- Magenta Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ: MGTA</a>) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.MarketBeat
- Magenta Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ: MGTA</a>) had its price target lowered by analysts at B. Riley from $21.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTAPR Newswire
- More
MGTA
SEC Filings
- 7/27/21 - Form 8-K
- 7/22/21 - Form 4
- 7/12/21 - Form 424B3
- MGTA's page on the SEC website
- More